Opus Genetics, Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Ocuphire Pharma, Inc. (to 2024)
0
Ending by 2030
Jan 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 28, 2027The maintenance fee for Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance (US 9,089,560) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
- 1 fee due Feb 8, 2027The maintenance fee for Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Performance (US 11,717,510) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof (US 11,844,858) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Highly Pure Phentolamine Mesylate (US 11,976,044) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,089,560 | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance In force · From the USPTO record | In force | From the USPTO record | |
| US 9,789,088 | Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Performance In force · Low confidence | In force | Low confidence | |
| US 9,795,560 | Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,278,918 | Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 10,772,829 | Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,000,509 | Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Performance In force · Medium confidence | In force | Medium confidence | |
| US 11,090,261 | Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,717,510 | Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Performance In force · Medium confidence | In force | Medium confidence | |
| US 11,844,858 | Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,350,366 | Aqueous Ophthalmic Solutions of Phentolamine and Medical Uses Thereof In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 23: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending